Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Lynn Henry

Showing results (31-40 of 195) with videos related to

Pageof 20
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2014
Assessment of PIK3CA mutations in human epidermal growth factor receptor 2-positive breast cancer: clinical validity but not utilityN Lynn Henry, Anne F Schott, Daniel F Hayes
Pharmacogenomics|March 28, 2017
Germline genetic predictors of aromatase inhibitor concentrations, estrogen suppression and drug efficacy and toxicity in breast cancer patientsDaniel L Hertz, N Lynn Henry, James M Rae
Women'S Health (London, England)|October 7, 2009
Adjuvant systemic therapy for elderly women with breast cancerN Lynn Henry, Kathleen M Diehl, Daniel F Hayes
Breast Cancer Research and Treatment|May 20, 2026
Change in practice patterns over time for endocrine therapy and radiation therapy in women with breast cancer age 65 and olderAubrey Stickland, Xueting Tao, Kelley Kidwell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 17, 2023
Testing for <i>ESR1</i> Mutations to Guide Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation UpdateHarold J Burstein, Angela DeMichele, Mark R Somerfield, et al.
Clinical and Translational Science|November 14, 2025
Pharmacokinetic-Pharmacodynamic Model of Paclitaxel-Induced Peripheral NeuropathyYuchen Sun, Manjunath P Pai, N Lynn Henry, et al.
Clinical Breast Cancer|April 19, 2023
Ovarian Function Suppression in Premenopausal Women With Concurrent Endocrine Therapy UseNicole M Grogan Fleege, Yajing Li, Kelley M Kidwell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 2, 2019
Reply to A. KatzN Lynn Henry, Fabrice Andre, Nofisat Ismaila, et al.
Plos One|January 22, 2025
Self-acupressure for patients with breast cancer experiencing aromatase inhibitor-associated musculoskeletal symptoms: Protocol for the AcuAIM randomized pilot trialN Lynn Henry, Kelley M Kidwell, Stephanie Kozar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 13, 2024
Endocrine and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer-Capivasertib-Fulvestrant: ASCO Rapid Recommendation UpdateHarold J Burstein, Angela DeMichele, Lesley Fallowfield, et al.
Pageof 20

Showing results (31-40 of 195) with videos related to

Sort By:
Pageof 20
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2014
Assessment of PIK3CA mutations in human epidermal growth factor receptor 2-positive breast cancer: clinical validity but not utilityN Lynn Henry, Anne F Schott, Daniel F Hayes
Pharmacogenomics|March 28, 2017
Germline genetic predictors of aromatase inhibitor concentrations, estrogen suppression and drug efficacy and toxicity in breast cancer patientsDaniel L Hertz, N Lynn Henry, James M Rae
Women'S Health (London, England)|October 7, 2009
Adjuvant systemic therapy for elderly women with breast cancerN Lynn Henry, Kathleen M Diehl, Daniel F Hayes
Breast Cancer Research and Treatment|May 20, 2026
Change in practice patterns over time for endocrine therapy and radiation therapy in women with breast cancer age 65 and olderAubrey Stickland, Xueting Tao, Kelley Kidwell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 17, 2023
Testing for <i>ESR1</i> Mutations to Guide Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation UpdateHarold J Burstein, Angela DeMichele, Mark R Somerfield, et al.
Clinical and Translational Science|November 14, 2025
Pharmacokinetic-Pharmacodynamic Model of Paclitaxel-Induced Peripheral NeuropathyYuchen Sun, Manjunath P Pai, N Lynn Henry, et al.
Clinical Breast Cancer|April 19, 2023
Ovarian Function Suppression in Premenopausal Women With Concurrent Endocrine Therapy UseNicole M Grogan Fleege, Yajing Li, Kelley M Kidwell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 2, 2019
Reply to A. KatzN Lynn Henry, Fabrice Andre, Nofisat Ismaila, et al.
Plos One|January 22, 2025
Self-acupressure for patients with breast cancer experiencing aromatase inhibitor-associated musculoskeletal symptoms: Protocol for the AcuAIM randomized pilot trialN Lynn Henry, Kelley M Kidwell, Stephanie Kozar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 13, 2024
Endocrine and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer-Capivasertib-Fulvestrant: ASCO Rapid Recommendation UpdateHarold J Burstein, Angela DeMichele, Lesley Fallowfield, et al.
Pageof 20